Bastide Le Confort Medical


FY revenue beat guidance

06/09/21 -"Bastide’s FY revenue was better than projected and the guidance for the underlying operating margin has been reconfirmed. Due to the one-off tailwind effect in this H1, the group forecasts a more ..."

Pages
45
Language
English
Published on
06/09/21
You may also be interested by these reports :
23/09/21
While the core business’s recovery momentum has sustained – reflecting in both the top-line and order book, cost headwinds due to higher supply ...

22/09/21
Orpea’s H1 results were broadly in line with analysts’ expectations and its real-estate portfolio continued enlarging. For FY21, the group reiterated ...

20/09/21
We used to see Fresenius (Buy, Germany) as a debt-financed acquisition-drive in the near certain business of public health. There is no such thing as ...

17/09/21
The material target price upgrade reflects Sonova’s sustainable technology leadership and strong fundamentals. Considering these important ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO